The application for the use of Clovis Oncology's PARP inhibitor Rubraca, or rucaparib, as a maintenance treatment for adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who exhibited at least a partial response to platinum-based chemotherapy was accepted for review by European regulators. The application was backed by data from a late-stage trial, in which the drug demonstrated significantly extended progression-free survival compared with placebo as a maintenance treatment for patients with ovarian cancer, regardless of BRCA status.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.